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Background: The involvement of the
immune system in heart failure (HF) has
been demonstrated. Evidence shows that
innate immunity can have a role in the
remodeling process and progression of
HF. With previous studies showing the
prognostic value of some innate immunity
markers and their relevance in this condition,
we aim to evaluate how these markers vary
on hospitalization due to an acute episode
of HF and at discharge. Methods: About
154 patients admitted with acute HF were
prospectively recruited. Patients were
evaluated on admission and at discharge
from the hospital. Patients with infection
were separately analyzed. Innate immu-
nity, inﬂammatory, and cardiac biomarkers
were measured and were compared
between groups and between admission
and discharge and with reference values
of biological variation. Results: Median
patients’ age was 78 years, and half of
the patients were men. The median dura-
tion of hospitalization was 6 days. C3 and
C4 protein levels signiﬁcantly increased
(P < 0.001) between admission and dis-
charge, as well as eosinophils (P < 0.001)
and BNP levels decreased (P < 0.001).
Variation in all these variables was inde-
pendent of infection and biological varia-
tion. Conclusion: Our results show that
innate immunity markers such as C3 and
C4 increase after treatment for acute
HF, supporting the hypothesis that they
can be involved in the resolution of the
acute episode. J. Clin. Lab. Anal.
30:1183–1190, 2016. © 2016 Wiley Peri-
odicals, Inc.
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INTRODUCTION
The well-established risk of hospitalization and death
and the continuous increase in incidence and prevalence
of heart failure (HF) make this condition a considerable
public health priority (1). Although brain natriuretic
peptide (BNP) is a major biomarker in HF (2), it unli-
kely reflects all the processes involved in this condition.
The activation of the immune system, alongside with
other pathways, has been receiving a growing interest.
Growing evidence indicates that patients with HF are
characterized by a state of chronic and systemic low-
grade inflammation, through the imbalance of its medi-
ators (3, 4). Activation of innate immunity may have an
even more important role in this condition, as both
infectious and/or noninfectious events could be
operating in HF (5, 6). Also, knowing that one of the
hallmarks of HF is the remodeling process in the heart,
innate immunity can have a predominant role in HF ini-
tiation and progression. In fact, after an event of acute
cardiac injury, such as myocardial infarction (MI), acti-
vation of the innate immune system is a prerequisite for
adequate healing (7). However, long-term chronic
innate immune activation is detrimental and may lead
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to adverse left ventricular remodeling and aggravation
of HF (8). Among all the innate immune system mark-
ers, the most well-studied are the toll-like receptors
(TLRs), with several experimental studies showing that
TLR2 and TLR4 may play a role in the progression of
HF (7, 9, 10). The inflammatory biomarker C-reactive
protein (CRP) (11) and other proinflammatory cytoki-
nes, such as tumor necrosis factor a (TNF-a) and at
least three interleukins (IL-1b, 6, and 18), have also
been associated with the failing myocardium (12, 13).
Knowing that the activation of innate immunity is not
limited to TLRs and that inflammation is known to be a
downstream effector of the innate immune system, it is
most likely that other innate immunity markers may be
activated in HF. In previous studies of our group, we
already demonstrated that lower levels of the comple-
ment protein C3, at the time of discharge, are a strong
and independent predictor of unfavorable outcome in
patients following an acute episode of HF (14). In this
context, we aimed to evaluate the variation in this and
other innate immunity markers in patients suffering




A prospective observational study was conducted
between January 2009 and December 2010. During
this period, 154 patients hospitalized due to an acute
episode of HF at the Internal Medicine Department of
S~ao Jo~ao Hospital Center, Portugal, were recruited.
Of the 154 patients, 21 had incomplete information,
leaving 133 patients for the current analysis. From
these patients, 55 were admitted with a precipitating
factor of infection for HF and/or had an infection
during hospitalization. These patients were separated
in a different group. Infection was defined by the deci-
sion of the attending physician to treat the patient
with antibiotics. Viral infection was not considered
once its frequency in hospitalized patients is rather
low. Worsening or de novo HF patients were
included. Patients with acute coronary syndrome were
excluded. Treatment and time of discharge were
decided by the attending physician. Clinical and demo-
graphic data and other relevant information, such as
medication, were collected through interview upon the
collection of the blood samples or by consulting medi-
cal registries. Comorbidities were recorded for each
patient. Coronary heart disease was defined as history
of MI, history or electrocardiographic evidence of
ischemia, or coronary angiography confirmation. Dia-
betes mellitus, anemia history, chronic arterial
hypertension, and chronic renal dysfunction were
defined as either the presence of previous diagnosis or
prescription of pharmacological treatment. Hospital-
ization days were calculated by the difference between
admission and discharge days. All patients provided
written informed consent to participate in the study.
The study protocol conforms to the ethical guidelines
of the Declaration of Helsinki and was approved by
the local ethics committee.
Blood sampling
Venous blood samples were collected from all patients
on admission and at discharge day into serum separator
and tripotassium ethylenediaminetetraacetic acid
(EDTA)-coated tubes (Venosafe, Terumo Corpora-
tion, Tokyo, Japan). An EDTA tube was used for
obtaining a complete blood count (CBC). The blood
samples for serum separation were allowed to clot and
then centrifuged, while EDTA tubes for plasma separa-
tion were immediately centrifuged for 15 min at
2,000 9 g. Serum and plasma samples were separated,
aliquot, and stored at 80°C for further analysis.
Methods
An echocardiogram was performed within 72 h of
admission to all eligible patients during hospitalization.
Comprehensive echocardiographic assessment was per-
formed using a multifrequency matrix probe (Vivid S6;
GE Healthcare, Little Chalfont, UK). The diagnosis of
HF was made based on the European Society of Car-
diology guidelines (15). An acute HF episode was
diagnosed: “de novo” HF on a first clinical presenta-
tion and chronic HF with clinical condition worsening,
both requiring urgent therapy. Patients with left ven-
tricular systolic dysfunction (LVSD) and with HF with
preserved ejection fraction were included in the reg-
istry. Normal systolic fraction was defined as a left
ventricular ejection fraction (LVEF) above 50%.
A CBC with leukocyte differential was obtained in
an automated blood counter Sysmex XE-5000 (Emilio
de Azevedo Campos, Senhora da Hora, Portugal). C1
inhibitor (C1i) and C3 and C4 complement proteins
were measured in a Dimension Vista 1500 nephelome-
ter (Siemens, Erlangen, Alemanha). CRP was mea-
sured in the automated clinical chemistry Olympus
AU5400 analyzer (Beckman-Coulter, Brea, CA). BNP
and Troponin I (TnI) were measured by a chemilumi-
nescent immunoassay in the Architect i2000 automated
analyzer (Abbott, Chicago, IL). IL-6 was measured by
way of an electrochemiluminescent immunoassay using
a Cobas E411 automated analyzer (Roche, Basel, Swit-
zerland).
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Statistical analysis
Continuous variables are presented as mean (stan-
dard deviation) or median (interquartile range)
depending on their distribution. Normality of the vari-
ables was tested by the Kolmogorov–Smirnov test.
Categorical variables are presented as counts and pro-
portions.
For comparing data between the admission and the
discharge date, a paired t-test was used for comparing
normal distributed variables, while the Wilcoxon test
was used for the nondistributed variables. For compar-
ison between the group with infection and without
infection, a one-way ANOVA test was used for normal
distributed variables and a Mann–Whitney test was
used for the nondistributed variables.
Mean percentage variation between admission and
discharge was calculated for all variables by subtract-
ing the value from discharge to the one of admission
and divided by the discharge value. These variations
were compared with biological variation published by
Ricos et al. (16).
The P value considered for statistical significance
was 0.05 for a confidence interval of 95%. Data were
collected and analyzed using SPSS software (v20.0;
SPSS Inc, Chicago, IL).
RESULTS
Median patients’ age was 78 years, and approxi-
mately, half of them were men (48.1%). The most
common comorbidity was chronic arterial hyperten-
sion, affecting 74.4% of the patients. Half of the
patients were on statin regimen, and more than 68%
were on a diuretic and/or renin–angiotensin–aldos-
terone system modulation regimen prior to admission.
Patients’ characteristics, comorbidities, and medication
are presented in Table 1.
Table 2 presents the laboratory values and changes
in the studied markers upon both evaluations, as well
as the comparisons between admission and discharge.
All of the complement proteins showed a significant
increase, higher than the accepted biological variation
(P < 0.001), from the initial hospitalization point up
to discharge. Regarding the cellular counts, neu-
trophils, eosinophils, and lymphocytes had a higher
variation than the accepted biological variation
(P < 0.001). Inflammatory (CRP and IL-6) and cardiac
injury (BNP and TnI) biomarkers are also presented in
Table 2. From all these markers, only BNP and TnI
changes were higher than the accepted biological varia-
tion. For IL-6, although there was a change between
admission and discharge (P = 0.037), there are no
available biological variation data to compare with.
Table 3 presents the same markers in the subgroup of
patients, which had infection as precipitating factor for
HF or had an infection during hospitalization. Unlike
for all patients, in this subgroup, the complement pro-
tein C4 showed no significant change (P = 0.076). Also,
unlike in the previous subgroup, in this subgroup,
leukocytes and basophils had higher changes than the
accepted biological variation (P < 0.001).
The laboratory values for the subgroup of patients
who did not had infection has a precipitating factor of
HF or had no infection during hospitalization are pre-
sented in Table 4. Also in these patients, all comple-
ment proteins showed a significant increase between
admission and discharge with higher variations than
the biological variation (P = 0.018 for C1i and
P < 0.001 for C3c and C4c). Regarding the inflamma-
tory markers, only CRP showed a significant decrease,
TABLE 1. Patients’ Demographics, Clinical Characteristics,
Comorbidities, and Medication
All patients (n = 133)
Clinical characteristics
Age (years), median (IQR) 78 (69; 84)
Male sex, n (%) 64 (48.1)
Ischemic etiology of HF, n (%) 68 (51.1)
Atrial fibrillation etiology of HF (%) 14 (10.5)
Valvular etiology of HF 0 (0.0)
Preserved LVSF, n (%) 51 (38.3)
NYHA class at admission (IV/III), n (%) 100 (75.2)
Comorbidities
Diabetes mellitus, n (%) 53 (39.8)
Anemia history, n (%) 53 (39.8)
Chronic arterial hypertension, n (%) 99 (74.4)
Chronic renal dysfunction, n (%) 23 (17.3)
Smoking habits, n (%)
Current smoker/ex-smoker 13 (9.8)/34 (25.6)
Alcohol habits, n (%) 62 (46.6)
Medication prior to admission
ACEi, n (%) 69 (51.9)
ARA, n (%) 22 (16.5)
Spironolactone, n (%) 19 (14.3)
Beta-blocker, n (%) 62 (46.6)
Nitrates, n (%) 32 (24.1)
Statin, n (%) 67 (50.4)
Diuretic, n (%) 92 (69.2)
Medication at discharge
ACEi, n (%) 99 (74.4)
ARA, n (%) 15 (11.2)
Spironolactone, n (%) 38 (28.6)
Beta-blocker, n (%) 99 (74.4)
Nitrates, n (%) 34 (25.6)
Statin, n (%) 86 (64.7)
Diuretic, n (%) 123 (92.5)
Hospitalization days, median (IQR) 6 (4.11)
IQR, interquartile range; HF, heart failure; LVSF, left ventricular
systolic function; NYHA, New York Heart Association; ACEi,
angiotensin-converting enzyme inhibitor; ARA, angiotensin II recep-
tor antagonist.
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but with lower variation than the biological variation
(as in the group of all patients—Table 2).
P values resulting from comparison at both
moments for both subgroups and for all patients
between both moments are presented for comparison
in Table 5. Laboratory values variation between both
moments of evaluation for the group of all patients as
well as the accepted biological variation is also pre-
sented. From all the markers in the study, only the
complement proteins C3 and C4, eosinophils, and
BNP had no significant differences between the sub-
groups in the study (differences independent of the
presence of infection, both P values higher than 0.05)
and presented a higher variation than the accepted
biological variation. These results are highlighted in
bold.
In all groups, the mean corpuscular hemoglobin
concentration (MCHC) was also evaluated, which
TABLE 2. Laboratory Values at Admission and at Discharge in All Patients and Comparison Between Admission and Dis-
charge
All patients (n = 133) Admission Discharge Variation (%)
Biological
variation (%) P value
C1i (mg/dl), median (IQR) 32.0 (28.2; 35.0) 33.7 (30.5; 37.4) 5.3 (15.9; 3.0) – <0.001
C3 (mg/dl), mean (SD) 116.1 (25.1) 133.4 (33.4) 20.6 (54.8) 5.2 <0.001
C4 (mg/dl), median (IQR) 24.9 (19.5; 30.8) 28.7 (22.1; 37.5) 14.3 (41.9; 4.8) 8.9 <0.001
Leukocytes (cells/ll), median (IQR) 7915 (6158; 10165) 7220 (5680; 8440) 7.0 (9.3; 25.5) 11.4 0.001
Neutrophils (cells/ll), median (IQR) 5905 (4108; 7943) 4660 (3520; 5770) 19.5 (4.6; 40.2) 17.1 <0.001
Monocytes (cells/ll), median (IQR) 510 (370; 700) 540 (440; 720) 5.9 (35.5; 18.3) 17.8 0.089
Eosinophils (cells/ll), median (IQR) 55 (10; 150) 140 (80; 240) 64.6 (250; 1.6) 21.0 <0.001
Basophils (cells/ll), median (IQR) 20 (10; 20) 20 (20; 40) 14.6 (100.0; 0.0) 28.0 <0.001
Lymphocytes (cells/ll), median (IQR) 1065 (710; 1603) 1430 (1080; 1950) 20.1 (72.1; 1.4) 10.2 <0.001
CRP (mg/l), median (IQR) 21.0 (10.2; 61.8) 13.2 (5.5; 25.2) 38.1 (4.5; 76.1) 42.2 <0.001
IL-6 (pg/ml), median (IQR) 17.3 (9.5; 38.1) 15.8 (8.3; 28.6) 24.3 (57.1; 57.3) – 0.037
BNP (pg/ml), median (IQR) 1287.1 (615.2; 2564.0) 599.0 (281.3; 1207.0) 48.2 (20.1; 72.9) 10.0 <0.001
TnI (ng/ml), median (IQR) 0.045 (0.190; 0.128) 0.027 (0.014; 0.051) 37.8 (0.8; 77.1) 14.1 <0.001
Hemoglobin (g/dl), mean (SD) 12.1 (2.1) 12.2 (2.0) 1.5 (9.2) 2.9 0.297
Hematocrit (%), mean (SD) 37.2 (6.2) 37.4 (5.7) 1.1 (9.4) 2.7 0.631
MCHC (g/dl), mean (SD) 32.6 (1.3) 32.7 (1.4) 0.5 (3.2) 1.1 0.104
IQR, interquartile range; SD, standard deviation; C1i, C1 inhibitor; CRP, C-reactive protein; IL, interleukin; BNP, B-type natriuretic peptide;
TnI, Troponin I; MCHC, mean corpuscular hemoglobin concentration.
Variation represents the median difference value between the admission and discharge values.
TABLE 3. Laboratory Values at Admission and at Discharge in Patients with Infection and Comparison Between Admission
and Discharge
Infected (n = 55) Admission Discharge Variation (%)
Biological
variation (%) P value
C1i (mg/dl), median (IQR) 32.9 (29.6; 36.2) 36.3 (31.8; 39.6) 6.7 (26.1; 0.9) – <0.001
C3 (mg/dl), mean (SD) 119.0 (26.3) 137.0 (31.0) 31.7 (77.4) 5.2 <0.001
C4 (mg/dl), median (IQR) 26.5 (19.6; 31.3) 28.9 (20.8; 38.9) 7.8 (39.8; 14.7) 8.9 0.076
Leukocytes (cells/ll), median (IQR) 8845 (6080; 11638) 7436 (5918; 9263) 14.1 (8.4; 30.8) 11.4 0.002
Neutrophils (cells/ll), median (IQR) 7170 (4858; 9125) 5250 (3508; 6505) 26.1 (0.1; 44.2) 17.1 <0.001
Monocytes (cells/ll), median (IQR) 520 (370; 763) 555 (460; 783) 5.9 (27.6; 21.3) 17.8 0.743
Eosinophils (cells/ll), median (IQR) 20 (0; 138) 145 (88; 263) 145.0 (750.0; 15.2) 21.0 <0.001
Basophils (cells/ll), median (IQR) 10 (10; 23) 30 (20; 40) 37.5 (145.8; 0.0) 28.0 <0.001
Lymphocytes (cells/ll), median (IQR) 900 (630; 1353) 1435 (1075; 1858) 42.3 (120.4;12.5) 10.2 <0.001
CRP (mg/l), median (IQR) 60.9 (28.4; 116.9) 21.4 (9.0; 39.2) 72.7 (24.0; 85.8) 42.2 <0.001
IL-6 (pg/ml), median (IQR) 29.4 (11.4; 53.2) 18.2 (9.4; 34.0) 37.7 (41.3; 79.5) – 0.009
BNP (pg/ml), median (IQR) 1333.5 (539.6; 2644.4) 713.0 (306.0; 1277.6) 48.5 (22.3; 64.0) 10.0 <0.001
TnI (ng/ml), median (IQR) 0.095 (0.039; 0.203) 0.038 (0.022; 0.083) 58.3 (21.4; 86.8) 14.1 <0.001
Hemoglobin (g/dl), mean (SD) 11.6 (1.9) 11.8 (1.6) 2.4 (9.9) 2.9 0.282
Hematocrit (%), mean (SD) 35.9 (5.8) 36.3 (4.3) 2.2 (10.1) 2.7 0.416
MCHC (g/dl), mean (SD) 32.5 (1.3) 32.6 (1.4) 0.3 (3.0) 1.1 0.516
IQR, interquartile range; SD, standard deviation; C1i, C1 inhibitor; CRP, C-reactive protein; IL, interleukin; BNP, B-type natriuretic peptide;
TnI, Troponin I; MCHC, Mean corpuscular hemoglobin concentration.
Variation represents the median difference value between the admission and discharge values.
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shows no significant differences in any of the groups in
the study.
DISCUSSION
Our data show, among a panel of biomarkers, that
C3 and C4 complement protein levels and eosinophils
counts all increase during hospitalization due to acute
HF, independently of infection and biological varia-
tion. However, BNP decreased independently of infec-
tion and biological variation.
The presence of a low-grade inflammatory state in
HF has been largely reported (17, 18). Although the
mechanisms of its activation in HF are still unclear,
TABLE 4. Laboratory Values at Admission and at Discharge in Patients Without Infection and Comparison Between Admission
and Discharge
Noninfected (n = 78) Admission Discharge Variation (%)
Biological
variation (%) P value
C1i (mg/dl), median (IQR) 31.0 (27.6; 34.1) 32.3 (29.4; 35.6) 3.0 (10.6; 4.9) – 0.018
C3 (mg/dl), mean (SD) 117.0 (24.4) 129.8 (34.8) 12.8 (28.3) 5.2 <0.001
C4 (mg/dl), median (IQR) 24.4 (19.5; 30.1) 28.3 (22.8; 34.5) 16.0 (44.2; 1.2) 8.9 <0.001
Leukocytes (cells/ll), median (IQR) 7230 (6170; 8918) 6750 (5650; 8115) 4.1 (9.8; 22.3) 11.4 0.094
Neutrophils (cells/ll), median (IQR) 5080 (3830; 7030) 4220 (3520; 5340) 11.5 (7.8; 34.9) 17.1 0.001
Monocytes (cells/ll), median (IQR) 510 (358; 650) 530 (420; 705) 5.9 (44.4; 14.6) 17.8 0.049
Eosinophils (cells/ll), median (IQR) 70 (23; 150) 140 (80; 230) 52.8 (136.5; 0.0) 21.0 <0.001
Basophils (cells/ll), median (IQR) 20 (10; 20) 20 (10; 30) 0.0 (100.0; 0) 28.0 0.001
Lymphocytes (cells/ll), median (IQR) 1175 (795; 1648) 1415 (1085; 1980) 13.7 (47.4; 5.7) 10.2 <0.001
CRP (mg/l), median (IQR) 12.0 (6.6; 20.5) 10.6 (4.0; 20.7) 28.6 (39.8; 56.1) 42.2 0.042
IL-6 (pg/ml), median (IQR) 14.4 (9.3; 23.1) 15.6 (7.7; 14.5) 8.5 (84.5; 50.5) – 0.768
BNP (pg/ml), median (IQR) 1265.1 (627.0; 2442.3) 536.4 (260.2; 984.0) 46.9 (13.8; 74.5) 10.0 <0.001
TnI (ng/ml), median (IQR) 0.029 (0.014; 0.070) 0.021 (0.012; 0.035) 30.8 (10.4; 63.4) 14.1 0.001
Hemoglobin (g/dl), mean (SD) 12.5 (2.2) 12.5 (2.2) 0.9 (8.7) 2.9 0.659
Hematocrit (%), mean (SD) 38.2 (6.4) 38.1 (6.4) 0.4 (8.9) 2.7 0.947
MCHC (g/dl), mean (SD) 32.7 (1.4) 32.9 (1.4) 0.6 (3.3) 1.1 0.124
IQR, interquartile range; SD, standard deviation; C1i, C1 inhibitor; CRP, C-reactive protein; IL, interleukin; BNP, B-type natriuretic peptide;
TnI, Troponin I; MCHC, mean corpuscular hemoglobin concentration.
Variation represents the median difference value between the admission and discharge values.
TABLE 5. Resume of Data (P values) from Comparisons Between the Group With Infection and the Group Without Infection













C1i (mg/dl), median (IQR) 0.036 <0.001 <0.001 5.3 –
C3 (mg/dl), mean (SD) 0.619 0.141 <0.001 20.6 5.2
C4 (mg/dl), median (IQR) 0.406 0.742 <0.001 14.3 8.9
Leukocytes (cells/ll), median (IQR) 0.016 0.122 0.001 7.0 11.4
Neutrophils (cells/ll), median (IQR) 0.001 0.041 <0.001 19.5 17.1
Monocytes (cells/ll), median (IQR) 0.224 0.341 0.089 5.9 17.8
Eosinophils (cells/ll), median (IQR) 0.081 0.715 <0.001 64.6 21.0
Basophils (cells/ll), median (IQR) 0.459 0.140 <0.001 14.6 28.0
Lymphocytes (cells/ll), median (IQR) 0.018 0.841 <0.001 20.1 10.2
CRP (mg/l), median (IQR) 0.001 <0.001 <0.001 38.1 42.2
IL-6 (pg/ml), median (IQR) 0.003 0.295 0.037 24.3 –
BNP (pg/ml), median (IQR) 0.727 0.473 <0.001 48.2 10.0
TnI (ng/ml), median (IQR) <0.001 0.001 <0.001 37.8 14.1
Hemoglobin (g/dl), mean (SD) 0.027 0.039 0.297 1.5 2.9
Hematocrit (%), mean (SD) 0.038 0.063 0.631 1.1 2.7
MCHC (g/dl), mean (SD) 0.403 0.222 0.104 0.5 1.1
IQR, interquartile range; SD, standard deviation; C1i, C1 inhibitor; CRP, C-reactive protein; IL, interleukin; BNP, B-type natriuretic peptide;
TnI, Troponin I; MCHC, mean corpuscular hemoglobin concentration.
Variation represents the median difference value between the admission and discharge values for all patients group. Bold values represent the
markers with no significant differences between the subgroups in the study and with significant higher variation than the accepted biological
variation.
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evidence suggests that myocardial damage may be
chronically sustained, implying a role for inflammatory
mediators (3, 19). The compensatory remodeling of
HF due to pressure overload or following cardiac
injury also attributes a predominant role to innate
immunity in HF and in its progression (20). Our data
corroborate these assumptions. The levels of the com-
plement proteins C3 and C4, an important participant
in the innate immunity response, showed a significant
increase between admission and discharge. Low levels
of these proteins are usually an indicator of high tissue
complement turnover that can mirror active remodel-
ing. The increase in their levels, on discharge, can indi-
cate the resolution of the cause of hospitalization and
their dynamic role in this condition.
For cellular counts, the changes that were found
between the admission and discharge were not always
higher than the accepted biological variation.
Although the increase in leukocytes is a marker of sys-
temic inflammation, the association with the risk of
HF is limited and sparse (21). The existent evidence
suggests an association between these cellular counts
and risk factors related to the development of HF,
such as coronary heart disease, MI, and stroke, with
worse prognosis in subjects who smoke and have
hypertension (21, 22). High leukocytes counts in mid-
dle-aged men were also associated with increased long-
term incidence of HF hospitalizations (22, 23). Our
patients only showed higher leukocytes counts at the
time of admission in comparison with the discharge in
the subgroup of patients with infection. This fact sug-
gests that higher counts of leukocytes can be related
with increased hospitalization of HF patients, but only
on those with an infection as precipitating factor of
HF. The leukocytes counts include several cellular sub-
sets, such as neutrophils, monocytes, eosinophils, and
basophils. These are known to have an important role
in inflammation, being representative of the cellular
innate immunity. Nevertheless, in HF, only some of
them were studied and associated with this condition.
An increase in neutrophils has been associated with
increased incidence of acute decompensated HF in
patients admitted with acute MI (24). A reduced circu-
lating eosinophil counts is associated with poor prog-
nosis after HF hospitalization with higher rates of all-
cause mortality in these patients (25). In fact, our
patients revealed these same tendencies, with signifi-
cantly higher counts of neutrophils at time of hospital-
ization in both subgroups of patients, with or without
infection. However, in the subgroup of patients with-
out infection, the variation was lower than the
accepted biological variation. Significantly lower
counts of eosinophils on admission, a situation
reverted upon discharge, were also found in all of the
groups studied. These variations were also higher than
the accepted biological variation. Unfortunately, no
data are available to compare with our data. The sig-
nificance of this observation probably merits further
investigation.
Regarding monocytes, limited data on the matter
show conflicting results. In patients with an existing
diagnosis of HF, it was reported that increased
monocyte counts were associated with HF and pre-
dicted worse outcomes (26, 27). However, the ARIC
study found no association between monocytes and
incident HF (23). In our data, monocyte counts only
showed a weak significant difference during hospital-
ization in the subgroup of patients without infection.
This may represent the well-known state of systemic
inflammation in HF patients and the well-known
role of these cells in the immune response. However,
it is now widely known that monocytes are a hetero-
geneous population of cells, each with distinct phe-
notypes and functions (28). This may be important
in understanding their specific role in HF. Recent
attention has been particularly directed toward the
“intermediate” (CD14++CD16+CCR2+) monocytes,
which appear to have prognostic significance in
cardiovascular disease (29). Although in our data,
monocytes counts did not revealed any statistical
significant changes, it does not mean that their
subpopulations did not changed. Thus, a possible
and important role of monocytes in HF should not
be discarded.
The presence of the inflammatory process is also
clear in the subgroup of patients with infection, with
higher levels of the proteins CRP and IL-6 at admis-
sion than at discharge. In patients without infection,
CRP did not reveal a significant decrease between
admission and discharge, independent of biological
variation. However, the association between CRP and
HF has already been reported, with high levels of
CRP as an indicative of severity of disease (11). CRP
mediates several protective processes, but may also
have deleterious effects in HF, such as the upregula-
tion of TNF-a and IL-6, which are a strong sign of
this activation (3, 19, 30). In fact, circulating levels of
proinflammatory cytokines are enhanced in the failing
myocardium, in both ischemic and nonischemic HF,
and are long known to be related to disease severity
and to predict poor survival (31, 32).
Also BNP, produced by the heart in the ventricles
and released in HF congestion due to cardiac chamber
stretch, and TnI, a specific marker of myocardial
injury, as expected (33), showed a significant difference
between admission and discharge, being higher on
admission in both subgroups and independent of the
presence of infection.
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Hemodilution can also be a major confounder factor
in our study, once it is expected that excess water had
been removed during hospitalization. To exclude this
confounder, we evaluated MCHC in all patients and
compared it between admission and discharge and
between groups, and no significant differences were
observed. Hence, this suggests that there was no
hemodilution effect in this study.
Few registries and clinical trials have prospectively
monitored parameters of innate immunity during
hospitalization. To our knowledge, this study is the
first to evaluate together both the humoral and cellu-
lar parts of innate immunity upon admission and at
discharge from hospitalization in a population suffer-
ing from acute HF. However, we acknowledge sev-
eral limitations. The small number of patients clearly
represents an important limitation. The recruitment
of patients and collection of samples both on admis-
sion and at discharge are a quite difficult task. It
depends on various factors, such as the time of hos-
pitalization of the patient, the outcome, the correct
and in time delivered informed consent, and avail-
ability of the on-call physician. The recruitment of
patients from a single center can also reveal a limita-
tion. Although our data lack the potential to be
external validated, we are strongly convicted that it
is an essential starting point for larger, multicenter
studies to be appropriately planned and powered.
Furthermore, our results are in agreement with our
previous study, where we document the prognostic
value of C3 and C4, at discharge, as predictors of
death patients suffering from an acute episode of
HF (14). Therefore, it is consistent with the hypothe-
sis that these proteins are involved in the progression
of HF.
Our results suggest that upon admission due to an
episode of acute HF, C3, C4, and eosinophils have
lower levels than at discharge from hospitalization,
independent of infection or biological variation. These
data help to support and reinforce that these innate
immunity effectors are active participants in HF and
may have an important role in the resolution of the
acute state of HF.
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